Usefulness of subcutaneous immunoglobulin therapy in the management of myasthenia gravis: a retrospective cohort study.

Marlène BarnayFanny DuvalGuilhem SoléLouis CarlaStéphane MathisGwendal Le Masson

Published in: Journal of neurology (2022)

SCIg is a well-tolerated and useful treatment in MG, offering interesting perspectives in the management of MG patients. However, further large-scale prospective studies are needed to confirm these results.

Keyphrases

myasthenia gravis
end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
peritoneal dialysis
patient reported outcomes
mesenchymal stem cells
bone marrow